Overall verdict
Neutral
6.0/10
1-year performance
+3.88%
Score breakdown
Up 3.9% over 1 year, 36% of the 52-week range.
Strongest: Profitability 9.6/10. Weakest: Growth 2.5/10.
23 analysts, target +0.1% vs the price.
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer.
It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions.
It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases; and strategic research collaboration with Engitix Ltd. to identify and validate novel therapeutic targets driving liver fibrosis regression.
The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.
Sector
Health Care
Industry
Pharmaceuticals
Primary listing
Lse
United Kingdom
CEO
Luke Miels
Founded
1715
Employees
66 841
Revenue / employee
496 503 GBP
Next earnings
February 3, 2027
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
22.82 GBP
52-week low
16.90 GBP
1-year performance
3.88%
Rising
Year-to-date performance
3.99%
Rising
Drawdown
-16.70%
Marked drawdown
Position in the 52-week range
36% of range
Range: 25.18 GBP - 32.38 GBP (comparables only)
The price implies growth of -3.17% per year; the company grows at -0.54%.
Gross margin 73.5%, net margin 13.0%, ROIC 12.2%, ROE 24.9%.
Net margin
12.97%
High
Sector 9.96%|S&P 13.40%
Gross margin
73.45%
Exceptional
Return on equity (ROE)
24.93%
Exceptional
Sector 6.73%|S&P 17.06%
Return on invested capital (ROIC)
12.17%
Exceptional
Free cash flow margin (FCF)
20.93%
Exceptional
Profit-to-cash conversion (FCF conversion)
1.61x
Exceptional
Margin stability
14.9 pts
Very uneven
Revenue to net income
Growth
2.5/10Revenue up 4.0% over 1 year, -0.9% a year over 5, EPS -0.5% a year over 5.
Revenue (trailing 12 months)
33.5Md GBP
Revenue growth (1y)
3.98%
Moderate
Revenue growth (3y)
11.40%
Moderate
EPS growth (1y)
123.32%
Hyper-growth
EPS CAGR (5y)
-0.54%
Declining
EPS revisions (3 months)
0.46%
Revised up
Valuation
5.2/10P/E 17.8x, forward P/E 15.4x, EV/EBITDA 9.1x, PEG 6.42. The multiple sits in the 51th percentile of its own 5-year history.
P/E (TTM)
17.8x
Fair
Sector 27.8x|S&P 23.6x
Forward P/E
15.4x
Fair
EV / EBITDA
9.1x
Fair
Sector 14.3x|S&P 15.5x
PEG
6.42
Very expensive
Sector 0.88|S&P 0.91
Fair value (reverse DCF)
28.78 GBP
Deeply undervalued
P/E vs its own 5-year history
among the 49% highest valuations
In line with its history
Market cap
75.6Md GBP
Financial strength
6.6/10Cash covers 12.5% of the debt, net debt/EBITDA 1.4x.
Net debt / EBITDA
1.4x
Solid
Gearing (net debt / equity)
112.95%
Stretched
Cash
2.9Md GBP
Cash / market cap
3.85%
Tight
Cash / total debt
12.50%
Stretched
Interest coverage
11.3x
Very solid
Net debt
20.4Md GBP
Equity
18.1Md GBP
Closed daily candles, 2 years
Last close on November 11, 2026: 18.87 GBP
- MM2018.75
- MM5018.45
- MM20019.54
- RSI 1453.8
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+0.16%
200-day average slope, 3 months
+0.61%
50-day average slope, 1 month
-0.44%
Price structure
Lower lows
Bullish RSI divergence
No
20-day volatility
1.78 % per day
Volatility change
+16.73%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 1.23 (12) | 1.79 (20) | 33 829 (22) | 11 526 (15) | 4 918 (10) |
| 2027 | 1.54 (12) | 1.88 (20) | 35 281 (20) | 12 248 (15) | 6 109 (10) |
Amounts in millions of GBP, EPS in GBP per share. In brackets, the number of analysts. Consensus as of November 11, 2026.
Same sub-industry: 503 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AZN | 7.1 | 7.0 | 286Md USD | 26.7x | 17.7 % | 7.1 % | 14.4 % | 1.2x | 3.6 % | 3.7 % | ||
| 2 | NOVO B | 6.2 | 7.7 | 178Md USD | 10.7x | 33.9 % | 5.6 % | 38.1 % | 0.7x | 6.0 % | -8.5 % | ||
| 3 | ROP | 6.2 | 6.4 | 385Md USD | 26.2x | 20.3 % | 1.7 % | 21.8 % | 0.8x | 4.7 % | 42.5 % | ||
| 4 | NOVN | 6.1 | 6.5 | 295Md USD | 32.0x | 18.0 % | 6.0 % | 13.5 % | 1.0x | 5.0 % | 29.2 % | ||
| 5 | LLY | 6.0 | 5.1 | 1.4T USD | 47.2x | 31.9 % | 38.6 % | 36.3 % | 1.2x | 1.5 % | 48.7 % | ||
| 6 | GSK | 6.0 | 6.2 | 100Md USD | 17.8x | 13.0 % | 4.0 % | 12.2 % | 1.4x | 9.3 % | 3.9 % | ||
| 7 | JNJ | 5.6 | 5.2 | 675Md USD | 42.5x | 16.2 % | 5.9 % | 13.6 % | 0.9x | 3.1 % | 48.1 % | ||
| 8 | MRK | 5.4 | 3.6 | 363Md USD | 150.3x | 3.6 % | 5.5 % | 2.6 % | 1.2x | 4.1 % | 68.5 % | ||
| 9 | PFE | 5.2 | 4.6 | 168Md USD | 42.1x | 6.3 % | -0.4 % | 2.7 % | 2.3x | 7.0 % | 20.3 % |
